<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (BD) is more common in eastern than western countries </plain></SENT>
<SENT sid="1" pm="."><plain>Physicians have frequently encountered problems in its treatment, especially eye involvement </plain></SENT>
<SENT sid="2" pm="."><plain>Recurrent oral and genital <z:e sem="disease" ids="C0038363" disease_type="Disease or Syndrome" abbrv="">aphthous ulcerations</z:e> are the hallmarks of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease but other organs can be involved and ocular disease is one of the most disabling manifestations </plain></SENT>
<SENT sid="3" pm="."><plain>Up to now, there are some problems in treatment of the <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> due to <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="4" pm="."><plain>We reported one patient, with <z:hpo ids='HP_0000572'>visual loss</z:hpo> due to <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> that was resistant to <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Our patient was treated successfully with rituximab and his remission was sustained for 24 months of follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>Rituximab is a chimeric monoclonal antibody that acts against the specific B cell antigen, CD20 </plain></SENT>
<SENT sid="7" pm="."><plain>The recent success of rituximab in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, which is considered to be T cell-mediated, indicates that B cells must have a much broader role in the pathogenesis of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> than generally appreciated </plain></SENT>
</text></document>